Meanwhile, Prevail Therapeutics is developing a gene therapy for a form of Parkinson's that is caused by mutations in the GBA1 gene, and Aspen Neuroscience is working on a personalised stem cell ...
Prevail said the FDA has granted Fast Track designation for its lead gene therapy, PR001 for treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback